All In Biotech

Drug Trial Radar · NCT05881811

The Drug-drug Interaction of HSK16149 Capsule With Probenecid Tablets or Cimetidine Tablets in Healthy Subjects

An Open-label Phase I Study to Evaluate the Drug-drug Interaction of HSK16149 Capsule With Probenecid Tablets or Cimetidine Tablets in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Dec 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Mar 20, 2023

Primary completion

Apr 24, 2023

Study completion Jun 5, 2023

Sponsor

Sponsor type
Industry
First posted
May 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single-center, open-label, crossover study, conducted in healthy Chinese populations, and plans to enroll 48 healthy adult subjects (male and female).

Conditions

  • PHN - Post-Herpetic Neuritis

Interventions

  • HSK16149,probenecid, cimetidineDrug

    40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: From the start to 72 hours after administration
  2. AUC0-tTime frame: From the start to 72 hours after administration
  3. AUC0-infTime frame: From the start to 72 hours after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Jishuitan Hoispital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.